BioSpace News Archive

Transgene and BioInvent International AB announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

BioInvent International AB and Transgene announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase 1/2a clinical trial for the treatment of patients with solid tumors.

Pharnext SA announces that findings on symptoms burden of Charcot-Marie-Tooth Disease Type 1A from the ‘Real-World’ Digital Lifestyle Study, CMT&Me, will be presented in three poster presentations at the upcoming International Congress on Neuromuscular Disease 2022.

Confo Therapeutics announced that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship.

MRM Health announced that they have received regulatory approval from the Federal Agency for Medicines and Health Products in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with Pouchitis.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a potential first-in-class Pol Theta Helicase development candidate.

Roivant Sciences and Pfizer announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality.

Kite, a Gilead Company, announces that the European Commission has approved its CAR T-cell therapy Yescarta® for the treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

Ascletis Pharma Inc. announces that the first subject has been dosed in the China Phase II clinical trial of ASC22 in combination with anti-retroviral therapy for immune restoration/ functional cure of human immunodeficiency virus 1 infection.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following industry and scientific conferences in July.